In the development lifecycle of peptide therapeutics, transitioning from milligram-scale laboratory synthesis to ton-scale commercial mass production in a peptide factory is a journey filled with strict technical challenges.

During the procurement process for peptide raw materials, many buyers engaging with a supplier for the first time fall into a common misconception: as long as the bench-scale sample they receive achieves a purity of 98% or higher, they assume the facility possesses excellent manufacturing standards and proceed to confidently place a bulk order.